Skip to content
Open access

Tumor Microenvironment-Triggered Dual-Prodrug Nanoplatform for Augmented Photodynamic Therapy: Self-Quenched Photosensitizer Activation and Nitric Oxide-Mediated Sensitization

Oct 2026 · Polymers · Vol 18 · 0 citations · 59 references
Medicine

Abstract

Photodynamic therapy (PDT) holds great promise for cancer treatment owing to its spatiotemporal selectivity and minimal invasiveness. However, its therapeutic efficacy is hampered by photosensitizer self-quenching and intrinsic tumor hypoxia. Herein, we construct a tumor-microenvironment (TME)-activated dual-prodrug nanosystem (PheoA-CSSE-JSK) integrating the photosensitizer prodrug PheoA and nitric-oxide (NO) prodrug JSK for targeted tumor delivery. Tumor-abundant glutathione (GSH) cleaves disulfide bonds to restore the photoactivity of PheoA, which generates reactive oxygen species (ROS) under near-infrared irradiation. Meanwhile, intracellular GSH/glutathione S-transferase (GST) triggers NO release from JSK. NO-derived reactive nitrogen species (RNS) can degrade the tumor collagen matrix, which is inferred to potentially relieve hypoxia and further boost ROS production. GSH consumption, together with NO-mediated inhibition of the mitochondrial respiratory chain, may further augment ROS levels. We propose a self-reinforcing ROS-amplification working model involving PheoA photoactivation, potential NO-associated hypoxia alleviation, GSH depletion, and mitochondrial respiratory-chain inhibition. Collectively, these combined effects facilitate mitochondrial-dependent apoptosis and prominent antitumor outcomes. This TME-responsive dual-prodrug nanoplatform provides a promising strategy to augment PDT against hypoxic tumors.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.